Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

August 28, 2017

In Canadian-Led Phase III Clinical Study, Xarelto® when Combined with ASA Significantly Lowered the Combined Risk of Stroke, Cardiovascular Death, and Heart Attack in Patients with Chronic Coronary or Peripheral Artery Disease by 24%

Read more
August 01, 2017

K9 Advantix® II approved for killing mosquitoes and reducing biting by mosquitoes and stable flies

Read more
July 07, 2017

RestoraLAX® recall expanded to include RestoraLAX 30+7 Bonus Packs

Read more
June 22, 2017

Bayer selects three Canadian startups for Grants4Apps® Toronto 2017 program

Supporting growth of digital healthcare in Canada part of Bayer Open Innovation Read more
May 05, 2017

Thousands of Canadians will benefit from a new training tool for surgeons

The National Research Council of Canada (NRC), with the support of Bayer Inc. through an innovation fund, has developed a first-of-its-kind pulmonary endarterectomy (PEA) surgery simulator that has the potential to improve the quality of life for thousands of Canadian patients. Read more
April 11, 2017

Bayer launches Grants4AppsToronto

Three digital health startups, 88 days and a once in a lifetime opportunity to be mentored by a global leader in life sciences Read more
March 20, 2017

Bayer's Canadian contraception family is growing with the launch of Kyleena®.

Kyleena is an effective, low-dose, five-year birth control option that women don't have to worry about taking every day. Read more
December 12, 2016

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols. BlueRock Therapeutics’ vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other conditions. Read more
November 07, 2016

Bayer is proud to be recognized as a top 100 employer for 10 years running

Bayer Inc. is excited to be recognized for the 10th time in a row as a Top 100 Employer in Canada. Bayer’s management team prides itself as having a stellar employee retention rate of some 96 per cent and employee satisfaction levels of 92 per cent and above. Read more
September 14, 2016

Bayer and Monsanto to Create a Global Leader in Agriculture

Realizes a shared vision of integrated agricultural offerings, delivering enhanced solutions for growers and creates a leading innovation engine for the next generation of farming. USD 128 per share in all-cash transaction, represents 44 percent premium to Monsanto shareholders and an aggregate value of USD 66 billion. Significant value creation with expected annual synergies of approximately USD 1.5 billion after year three; plus additional synergies from integrated solutions in future years. Bayer shareholders expected to benefit from accretion to core EPS in the first full year after closing and double-digit percentage accretion in the third full year. Committed to retaining strong presence in the U.S. with the combined business’ global Seeds & Traits and North American commercial headquarters in St. Louis. Read more